The novel enterovirus protease inhibitor (PI) SG85 effectively inhibits the in vitro replication of 14 rhinoviruses representative of species A and B (median 50% effective concentration, 0.04 M). A low-level SG85-resistant variant was selected that carried amino acid substitutions S127G and T143A in the 3C protease. Both substitutions are required for low-level resistance to SG85, as demonstrated by reverse genetics. Interestingly, there is no cross-resistance to SG85 and rupintrivir (another PI); a structural explanation is provided for this observation. R hinoviruses (RV) are nonenveloped, positive-sense, singlestranded RNA viruses that belong to the family of Picornaviridae, genus Enterovirus (1). Currently, more than 150 RV have been identified, which genotypically group into RV-A, RV-B, and RV-C (2). RV infections not only cause common colds but may also trigger exacerbations of asthma and chronic obstructive pulmonary disease (COPD) (3-5). Because of the high (and still rising) number of variants, development of a vaccine will be hard to achieve. Therefore, treatment with antivirals is a more realistic strategy to reduce the burden of these infections. An RV inhibitor, in particular, is needed for the prophylaxis and treatment of RVinduced exacerbations of asthma and COPD (6).
R
hinoviruses (RV) are nonenveloped, positive-sense, singlestranded RNA viruses that belong to the family of Picornaviridae, genus Enterovirus (1). Currently, more than 150 RV have been identified, which genotypically group into RV-A, RV-B, and RV-C (2). RV infections not only cause common colds but may also trigger exacerbations of asthma and chronic obstructive pulmonary disease (COPD) (3) (4) (5) . Because of the high (and still rising) number of variants, development of a vaccine will be hard to achieve. Therefore, treatment with antivirals is a more realistic strategy to reduce the burden of these infections. An RV inhibitor, in particular, is needed for the prophylaxis and treatment of RVinduced exacerbations of asthma and COPD (6) .
The RV 3C protease (3C pro ) is a promising target for drug development efforts because of the high level of conservation in its substrate-binding site, its role as an indispensable enzyme for virus replication, and its unique cleavage specificity (after Gln), which has not been observed in any other known host cell protease (7) (8) (9) (10) (11) . Peptidomimetics with Michael acceptor warheads permanently disable the protease by covalent binding to its catalytic site (12, 13) . The peptidomimetic rupintrivir (Pfizer AG7088; Fig. 1 ) effectively inhibits RV and enterovirus replication in vitro but largely failed to fulfill its promise in clinical trials (14) (15) (16) (17) .
Comparison of the known crystal structures of enterovirus 3C pro s revealed that the enterovirus 68 (EV68) 3C pro can be considered an intermediate between the proteases of RV02 and poliovirus (18) . Therefore, it was selected for the design of broadspectrum enterovirus 3C pro inhibitors, yielding SG85, a peptidic ␣,␤-unsaturated ethyl ester with Michael acceptor properties, as the most promising candidate. SG85 is an efficient inhibitor of EV68 3C
pro and inhibits the replication of enteroviruses in cellbased assays (18, 19) .
We demonstrate here that SG85 effectively inhibits the replication (in multicycle virus-cell-based cytopathic effect [CPE] reduction assays [20] ) of 14 RV serotypes that are representative of RV-A and -B (Table 1) . Median 50% effective concentrations (EC 50 s) of 0.04 Ϯ 0.02 M and 0.02 Ϯ 0.01 M were obtained against RV-A and RV-B, respectively. The 3C pro inhibitor rupintrivir (Axon Medchem, The Netherlands) was, on average, 4-fold more active (Table 1) , but this varied with the type (e.g., equipotent activity against RV63 and 14-fold more potent against RV02). Akin to rupintrivir, SG85 also strongly inhibited the replication of enterovirus 71 (EV71) and, to a lesser extent, protected cells against coxsackievirus B3 (CVB3), echovirus 11 (ECHO11), and poliovirus 1 (PV1) replication (18) ( Table 1) .
Serial passaging with increasing concentrations of SG85 for extended periods of time did not result in the isolation of SG85-resistant RV14 virus variants (data not shown). Instead, a clonal selection procedure was used. To this end, several hundred infected cultures (in 96-well plates) were treated with a fixed concentration of the compound studied equal to the EC 99 or a higher concentration. Supernatants collected from those few cultures where a CPE developed under drug pressure were selected for further expansion of the virus (20) . Using this method, we obtained resistant variants in 1 out of 20 cultures in the case of pleconaril (data not shown), whereas for SG85, such variants were observed in only 1 of 273 cultures. This suggests that the virus quasispecies of the inoculum contained very few variants with some natural level of resistance to the compound and/or that it is very difficult for the virus to acquire these substitutions. The variant that was obtained proved to be Ͼ4-fold less sensitive than the wild-type virus to the antiviral effect of SG85 (data not shown). Such a low level of drug resistance may not be clinically relevant. However, other factors, such as the pharmacokinetic profile of the compounds in humans, will contribute as well. Genotyping revealed double mutations in the 3C pro -encoding gene (S127G and T143A). To confirm the causal link between the mutant genotype and the resistant phenotype, single and double mutants were generated by using an infectious clone of RV14 (D. Blaas, Vienna, Austria; referred to as RV14 IC here). The two single mutants, i.e., those that carried either S127G or T143A, did not show decreased susceptibility to the antiviral effect of SG85 (Table 2) . However, the double mutant (RV14 IC S127G T143A) has low-level resistance and proved 3-fold less susceptible than wild-type RV14 IC to the antiviral effect of SG85. Of note, the sensitivity of any of the mutants to rupintrivir was not altered ( Table 2 ). The reverseengineered double mutant had a level of resistance (3-fold) comparable to that of the phenotypically selected variant. It has been reported that in vitro-selected rupintrivir-resistant RV14 (7-to 16-fold resistant) carries four substitutions (i.e., T129A, T131A, Y139H, T143P) in 3C (21) . Even though the quadruple mutant also carries a substitution at position 143 (21), we did not observe cross-resistance between SG85 (which selects for the substitutions S127G and T143A) and rupintrivir ( Table 2 ). In the same study, reverse-engineered variants with a single substitution, including one at position T143, showed no reduced susceptibility to the antiviral effect of rupintrivir (21) . This is in line with our observations that besides the substitution T143A, the substitution S127G in 3C pro is also required for resistance to the Michael acceptor-based peptidomimetic SG85.
SG85 and rupintrivir are less active against enterovirus species B and C (Table 1) . For a better understanding, a sequence alignment was made of 3C pro of the RV strains that were used in this study, along with the 3C sequences of an RV-C15 isolate (W1, GU 219984.1), CVB4, PV1, and EV68 (Fig. 2) . The serine residue at position 127 was conserved throughout the RV strains. At the corresponding position (residue 128), EV68 and PV1 carry a glycine, which corresponds to the substitution that was detected in the low-level SG85-resistant RV14 variant. A crystal structure of RV02 3C
pro in complex with a peptidic Michael acceptor (compound III) revealed the presence of a hydrogen bond between the backbone amide of the P2 residue of the inhibitor and the side chain oxygen of S128 (22) . It may be assumed that the same interaction will exist in the SG85 complex of the RV14 protease and will thus be lost with the S127G substitution, presumably resulting in a loss of free energy of binding that decreases the efficiency of the inhibitor. Rupintrivir, however, lacks a P2 backbone amide and such a hydrogen-bonding interaction, and therefore, the S127G substitution does not accumulate as part of a drug resistance mechanism. It should be noted that we made multiple attempts to express both the wild-type and mutant proteases. However, be- cause of the limited solubility of these proteins, we were not able to biochemically characterize these enzymes. The threonine at position 143 is conserved in the RV-B strains, whereas the majority of RV-A strains carry a serine (at corresponding position 144) and the RV-C strain included in this analysis carries a proline. It remains to be determined whether RV-C (3C pro ) is sensitive to SG85 (and/or rupintrivir). For RV89, EV68, and PV1, an alanine residue is present at this position, which was also detected in the low-level SG85-resistant RV14 variant. The crystal structures of EV68 3C pro in complex with SG85 (18) and of RV 3C pro in complex with compound III or rupintrivir (22) reveal that whereas the main chain of residue 144 is part of the S1 pocket of the protease, its side chain, whether Ala or Ser/Thr, is oriented away from the inhibitor; therefore, it is not immediately clear how the S/T143A substitution would affect the binding of the compound. In agreement with these observations, both the RV14 IC S127G T143A double mutant and PV1 show decreased susceptibility to the antiviral effect of SG85, whereas RV89 (which is akin to the RV14 IC single mutant, carries only A143) is inhibited as well as wild-type RV14 IC .
Protease inhibitors (PI) are being successfully used for the treatment of infections with HIV and hepatitis C virus. The development of novel RV and enterovirus 3C inhibitors should be considered further. Such inhibitors have the potential to exert broadspectrum antiviral activity and (unlike with most HIV and HCV PI) high-level drug-resistant variants do not, or at least do not readily, develop. Moreover, we demonstrate here that PI of enterovirus and RV 3C with nonoverlapping drug resistance profiles can be developed.
